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Abstract
Background: The goal of this study was to validate
the DiaSorin Liaison BAP OSTASE, a new method for
measurement of bone alkaline phosphatase (BAP), and to
compare this method with the Beckman-Coulter Access
Ostase. We also wanted to establish the reference range for
BAP in adults and children.
Methods: We determined the precision, functional sensitiv-
ity, recovery, linearity and measurement uncertainty, accu-
racy profile and b-expectation limits. We defined an adult
reference interval using individuals with 25-OH vitamin D
)80 nmol/L, parathormone -58 ng/L, and normal calcium,
phosphorous and estimated glomerular filtration rate. Each
adult subclass (men/non-menopausal women/menopause
women) contained 120 individuals. We also determined the
2.5th and 97.5th percentiles from a population of 450 chil-
dren, stratified according to age and gender.
Results: The results of the validation showed: precision
-6%, functional sensitivity -0.74 mg/L, mean recovery
98.8"4.2% and good linearity. Relative uncertainty ranged
from 9.0% to 12.9%, and the risk of one result falling out
of the "15% acceptance limits was -5% for concentrations
between 7 and 94 mg/L. The Bland-Altman plot showed no
systematic bias between the two methods. In adults, we did
not find any statistical difference between the different sub-
classes. The upper limit of normality observed in the entire
population (ns360) was 21.3 mg/L (90% CI: 18.3–24.2
mg/L).
F.R.S.-FNRS Postdoctoral Researcher (Belgium).a
*Corresponding author: Dr. Etienne Cavalier, Department of
Clinical Chemistry, University Hospital of Lie`ge, Domaine du
Sart-Tilman, 4000 Lie`ge, Belgium
Phone: q32 4 3667692, Fax: q32 4 3667691,
E-mail: Etienne.cavalier@chu.ulg.ac.be
Received August 1, 2009; accepted September 2, 2009;
previously published online November 30, 2009
Conclusions: The Liaison BAP OSTASE is a robust method,
and is completely validated between 7 and 93 mg/L: in this
range, 95% of the values obtained will be within "15% of
the true value.
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Introduction
Bone alkaline phosphatase (BAP) was discovered in 1923 by
Dr. Robert Robinson from the Lister Institute (1). BAP is
one isoform of the alkaline phosphatases, which originates
from many tissues, but primarily the liver and bone. BAP
is a tetrameric glycoprotein attached to the osteoblast
membrane by a carboxy-terminal glycan-phosphatidylinosi-
tol anchor. The action of a phospholipase releases BAP as a
homodimer from the membrane into the circulation (2). Once
in the blood stream, the half-life of BAP is relatively long
(1–2 days), which most likely contributes to its low diurnal
and biological variability (3). The exact function of BAP
remains unknown. However, it has been suggested that it
might play a role in mineralisation of newly formed bone.
Indeed, patients suffering from hypophosphatasia, a rare
inborn error of metabolism caused by low activity of the
tissue-non-specific isoenzyme of alkaline phosphatase, pres-
ent with severe osteomalacia. BAP is a useful marker in rare
diseases where its concentration is particularly high such as
Paget’s disease of bone or tumour-induced osteomalacia.
However, it is most often used as a marker of bone remod-
elling during follow-up of osteoporosis. Since it is cleared
by the liver (4) and therefore not affected by kidney disease,
BAP also represents an interesting alternative to parathyroid
hormone (PTH) in the follow-up of patients suffering from
renal osteodystrophy. Commercially available immunoassays
have been developed for measurement of BAP. These assays
measure either the activity or the mass of the enzyme. The
goal of this study was to evaluate the analytical performance
of the BAP OSTASE (DiaSorin, Stillwater, MN, USA). This
method has been made available recently on the Liaison plat-
form. We wished to compare the performance of this kit with
the Beckman-Coulter Access (Beckman-Coulter, Brea, CA,
USA). We also defined the reference interval of this para-
meter in a well described ‘‘normal’’ adult population and in
children.
68 Cavalier et al.: Analytical validation of BAP
Article in press - uncorrected proof
Table 1 Precision observed in three serum controls.
Control n Mean, mg/L Within-run Total
SD CV, % SD CV, %
1 15 15.87 0.62 3.9 0.76 4.7
2 15 21.51 0.56 2.6 1.05 4.9
3 15 31.14 1.50 4.8 1.81 5.8
Table 2 Measurement uncertainty observed in 6 control samples.
Control Mean, Uncertainty, Relative b-Expectation Relative Risk, %
level mg/L mg/L uncertainty, % tolerance limit, mg/L b-expectation
tolerance limit, %
1 6.20 0.78 12.63 w5.243, 7.157x w–15.44, 15.44x 7.636
2 15.87 1.62 10.19 w14.06, 17.68x w–11.39, 11.41x 1.923
3 21.51 2.27 10.52 w18.73, 24.29x w–12.90, 12.93x 4.006
4 31.14 3.81 12.22 w26.93, 35.35x w–13.52, 13.52x 4.182
5 51.60 4.65 9.00 w46.60, 56.60x w–9.692, 9.692x 0.6298
6 93.90 12.14 12.93 w80.08, 107.7x w–14.72, 14.72x 6.057
Materials and methods
Analytical methods
The Liaison BAP OSTASE is a two-site sandwich immunoassay
that utilises two purified mouse monoclonal antibodies for capture
and detection of BAP. Serum is incubated with paramagnetic par-
ticles coated with BAP monoclonal antibody (Mab). After incuba-
tion, a second mouse Mab conjugated to isoluminol is added. After
another short incubation, a chemiluminescent reaction occurs fol-
lowing addition of the starter reagent. The light signal is propor-
tional to the concentration of BAP present in the sample. The
Liaison BAP OSTASE has been calibrated against the Beckman-
Coulter Access Ostase.
The Beckman-Coulter Access Ostase is a chemiluminescent
immunoenzymatic one-step assay based on capture of the analyte
by a mouse Mab specific to BAP and fixation of the complex by
paramagnetic particles coated with goat ant-mouse polyclonal anti-
body. Following the formation of the solid phase-capture Mab-BAP,
particles are separated in a magnetic field and washed. A chemi-
luminescent substrate for alkaline phosphatase is added and fluo-
rescence is measured with a luminometer. Light production is
directly proportional to the amount of BAP captured by the Mab.
The Access Ostase is an activity-based immunoassay, whereas the
Liaison BAP OSTASE is mass-based. The Access Ostase has been
matched to the calibration established with the Tandem-R-Ostase
IRMA, a mass-based radioimmunoassay.
Statistical software
We used Medcalc (Mariakerke, Belgium) and e-noval (Arlenda,
Lie`ge, Belgium) software for statistical evaluation of the results.
Samples
We validated the BAP Liaison assay using serum samples.
Validation protocol
For validation, we evaluated the precision in accordance with a
modified protocol based on CLSI EP-5A2 (5). Three homemade
serum controls were assayed in triplicate once per day for 5 days.
The limit of quantification was defined as the lowest value giving
an inter-assay coefficient of variation of 20%, determined over
10 days. Linearity was evaluated in accordance with CLSI EP-6A
(6) and recovery was determined according to CLSI EP-6P (7).
Finally, we evaluated measurement uncertainty, accuracy and the b-
expectation limits by analysis of six serum pools in triplicate over
5 days.
Measurement uncertainty characterizes the dispersion of the val-
ues around the true value and b-expectation tolerance limits with
bs0.95 are the upper and lower values in-between which each
future measurements of the same level has a probability of 95% to
be found (8, 9). Accuracy characterises the performance of the
method and refers to the closeness of agreement between a result
obtained with the method and results obtained with the reference
method (10). Since no certified material is available for BAP, we
used the mean of each pool as the expected value.
Comparison with the Beckman-Coulter Access
We compared the results obtained with the two methods in 83
consecutive samples from our daily routine using Bland-Altman
analysis (11).
Establishment of the reference range
We defined our adult normal population as healthy individuals pre-
senting with PTH concentrations -58 ng/L (on DiaSorin Liaison),
25-OH vitamin D w25(OH)Dx )80 nmol/L (DiaSorin Liaison), an
estimated glomerular filtration rate )60 mL/min/1.73 m2 wisotope
dilution mass spectrometry (IDMS) traceable creatinine compensat-
ed Jaffe´ method from Roche Diagnostics on Modular P, Mannheim,
Germanyx, and calcium and phosphorus concentrations falling with-
in the laboratory’s reference range (also on Modular P). We rejected
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Figure 1 Accuracy profile of the DiaSorin Liaison BAP OSTASE.
When the b-expectation limits (broken lines) are comprised between the maximum total allowable error (determined to be "15%), the
method is considered as valid.
Figure 2 Bland-Altman plot for BAP measured in 83 patients with the Liaison BAP OSTASE and the Beckman-Coulter Access Ostase.
Results given in mg/L.
any individual who presented with C-telopepide of type I collagen
concentrations (determined with the b-Crosslaps kit of Roche Diag-
nostics on Elecsys) higher than the expected reference range. All
samples were collected between July and December 2008 and stored
for a maximum of 1 month at –208C before measurement of BAP.
We divided our population in three sub-groups of 120 individuals:
males, non-menopause females and menopause females. We used
the Kolmogorov-Smirnov test to determine if the population was
Gaussian, and non-parametric methods for non-Gaussian distribu-
tions. We took the upper 95% as the upper limit of normality.
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Table 3 Description (mean"SD) of the adult population used for
establishing the reference range.
Male Non-menopause Menopause
female female
n 120 120 120
Age, years 57.2"16.8 31.3"5.3 67.3"7.7
25(OH)D, nmol/L 94"15 102"25 96"17
PTH, ng/L 40"10 35"10 40"10
Figure 3 Age related BAP distribution in young boys.
We also measured BAP in children. The children tested had
undergone collection of blood for allergy testing. None were suf-
fering from bone disorders, delayed puberty or growth deficiency.
Each age category (from 0 to 18 years, 2 years by 2 years) and
gender comprised 25 individuals.
Results
Analytical performance
The results of the precision evaluation are shown in Table 1.
As seen in Table 1, repeatability did not exceed 5% and the
intermediate precision was 6% at a concentration range of
15–31 mg/L. The functional sensitivity was 0.74 mg/L and
mean recovery was 98.8%"4.2%. The manufacturer states
that the kit is linear up to 120 mg/L. By diluting two high
samples (80 and 115 mg/L), we found that the method was
linear up to a 1/10 dilution.
Measurement uncertainty and b-expectation tolerance lim-
its observed using the six pools are presented in Table 2.
Measurement uncertainty was between 9.0% and 12.9%. The
b-expectation tolerance intervals were computed at each
concentration with a probability of bs95%. Stated differ-
ently, on average, 95% of the future results generated by this
method will be included in the established tolerance inter-
vals. The method for establishing tolerance intervals is pre-
dictive. The method will provide accurate results if the 95%
b-expectation tolerance interval at each concentration is
included in the acceptance limits established at "15%
waccording to (12)x. Figure 1 illustrates this using an accuracy
profile. As shown on Figure 1, the method provides accurate
results between 7 and 94 mg/L. These values represent the
lower and upper quantitation limits, respectively, and define
the range of the method. Future results are assumed to be
within "15% of the actual value with a probability of 95%.
Comparison with Beckman-Coulter Access Ostase
Figure 2 shows the Bland-Altman plot. The values ranged
from 3.7 to 80.2 mg/L and there was no systematic bias
between the two methods (mean differences0.3 mg/L). The
standard deviation (SD) of the differences was 5.7 mg/L. We
did not find any significant difference using the Wilcoxon
test wmedian (95% CI): Liaison: 12.8 mg/L (9.4–21.4) and
Access: 14 mg/L (10.8–17.2)x. The regression between the
two methods is Accesss0.9123=Liaisonq2.0025 (R2s
0.9006, p-0.001).
Values observed in the population
Our selected population for establishing an adult range
showed a mean 25(OH)D concentration of 92.5 nmol/L
wlowest (L): 80; highest (H): 145x, a mean PTH of 38 ng/L
(L: 18–H: 57) and a mean age of 58 years (L: 22; H: 85).
The description of each subclass (men/women/menopause
women) is presented in Table 3. In men, the BAP cut-off
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Figure 4 Age related BAP distribution in young girls.
Table 4 Percentiles 2.5th and 97.5th observed when BAP was
determined in young boys and girls.
Age, years No. in each Boys, Girls,
gender mg/L mg/L
category
From 0 to -3 25 43.4–104.8 41.9–107.0
From G3 to F4 25 29.7–84.8 29.5–108.5
From G5 to F6 25 48.8–109.0 21.9–115.4
From G7 to F8 25 52.6–123.0 37.1–147.9
From G9 to F10 25 52.3–105.4 42.0–107.6
From G11 to F12 25 55.7–152.3 38.6–111.2
From G13 to F14 25 15.5–134.0 13.7–109.8
From G15 to F16 25 16.6–127.9 10.2–72.6
From G17 to F18 25 11.0–77.6 5.9–20.0
was 20.3 mg/L (90% CI: 16.1–25.2 mg/L), 23.6 mg/L in
non-menopause women (90% CI: 16.9–26.6 mg/L) and
20.4 mg/L in menopause women (90% CI: 17.8–25.0 mg/
L). There was no statistical difference between the three pop-
ulations and we therefore combined all the data. The higher
upper limit of normality observed in the entire population
(ns360) was 21.3 mg/L (90% CI: 18.3–24.2 mg/L).
Figures 3 and 4 show the age-related BAP distribution
among children. We observed a peak between 7 and 8 years
for girls, whereas boys showed the peak to be later, between
11 and 12 years. Until 7–8 years of age, there was no sig-
nificant difference between the values observed in children,
whereas significant age-related differences were observed at
older age. Table 4 gives the 2.5th and 97.5th percentiles
observed in children, classified by age and gender. Each val-
ue higher than the upper validated range (94 mg/L) was
obtained after dilution of the sample.
Discussion
We present the results of the analytical validation of the
Liaison BAP OSTASE. Our results show that this method is
sensitive and precise. We also established the measurement
uncertainty and showed that for values between 7 and 94
mg/L, 95% of the results will be within "15% maximum
allowable total error. The results of the Liaison BAP
OSTASE agree with those obtained with the Beckman-Coul-
ter Access Ostase. We established a reference range in a
population that we defined as ‘‘normal’’, although this con-
cept is rather controversial. We defined our reference popu-
lation as adults presenting with ‘‘normal’’ 25(OH)D con-
centrations and no other causes of hyperparathyroidism (13).
This approach is quite new, as these parameters are not gen-
erally taken into consideration when establishing reference
ranges for bone markers (14). This point is important, as we
have shown that in our defined reference population, there
was no difference between males and non-menopause/meno-
pause females. Differences are usually observed in less well-
defined populations. We also provided values from 450 chil-
dren classified according to age and gender. Even though our
population of children cannot be considered a ‘‘reference’’
population, this information can be helpful to laboratories
and paediatricians.
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